AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02498002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Energy Intake Monitoring
Description: Monitor energy intake by weighing and recording all foods/drinks consumed during the required periods.
Study NCT02498002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Intake Monitoring
Description: Monitor energy intake by weighing and recording all foods/drinks consumed during the required periods.
Study NCT04126395 — intervention group
Intervention type: OTHER
Intervention: Retrospective Video Analysis
Description: Retrospective video analysis will be used to explore motor development in children with DCD, DCD+ASD and controls.
Study NCT02498002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body Weight Monitoring
Description: Monitor body weight during monitoring phase to ensure stability despite other monitoring activities.
Study NCT02498002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Weight Monitoring
Description: Monitor body weight during monitoring phase to ensure stability despite other monitoring activities.
Study NCT02958722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: physiological solution
Study NCT02498002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Cannulation
Description: Fitting of an intravenous cannula to a vein on the forearm for blood sampling during laboratory protocols.
Study NCT02498002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous Cannulation
Description: Fitting of an intravenous cannula to a vein on the forearm for blood sampling during laboratory protocols.
Study NCT02958722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbon dioxide
Study NCT02498002 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adipose Tissue Biopsy
Description: This is an optional feature which if included involves the removal of a 0.5 gram sample of adipose tissue from just below the skin using a needle.
Study NCT02498002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose Tissue Biopsy
Description: This is an optional feature which if included involves the removal of a 0.5 gram sample of adipose tissue from just below the skin using a needle.
Study NCT02498002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: The anaesthetic that will be used to numb the site of the adipose tissue biopsy in the event it is included.
Study NCT02498002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: The anaesthetic that will be used to numb the site of the adipose tissue biopsy in the event it is included.
Study NCT02498002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post-Prandial Meal Tests
Description: Consume two successive meals with regular blood samples throughout the ensuing hours (2-3 hours each).
Study NCT02498002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Prandial Meal Tests
Description: Consume two successive meals with regular blood samples throughout the ensuing hours (2-3 hours each).
Study NCT02498002 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: DEXA Scan
Description: Undergo a dual energy x-ray absorptiometry scan to examine body composition.
Study NCT02498002 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DEXA Scan
Description: Undergo a dual energy x-ray absorptiometry scan to examine body composition.
Study NCT02498002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Actiheart Calibration
Description: Submaximal treadmill test to calibrate monitoring equipment.
Study NCT02498002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actiheart Calibration
Description: Submaximal treadmill test to calibrate monitoring equipment.
Study NCT02498002 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Daily Calorie Restriction
Description: Reduce energy intake by 25% on a daily basis.
Study NCT03249285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peri
Description: Perindopril 4 mg /day, orally with titration to 8 mg/day after 1 month if BP (Blood pressure) is not controlled
Study NCT00680654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: The investigational drug will be given twice per subject, as single dose administration of BAY 63-2521 (0.5 mg and 1.0 mg) during the hemodynamic investigation.
Study NCT00576550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea
Description: Urea cream applied twice daily up to six months
Study NCT00576550 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: betamethasone valerate
Description: Application once daily for two weeks
Study NCT00576550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betamethasone valerate
Description: Application twice daily for two weeks
Study NCT01352026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT03956927 — intervention group
Intervention type: OTHER
Intervention: S-TPE
Description: S-TPE stimulation session with groups of 8 patients. The simulation is performed by a single patient, the others are observers in a neighbouring room where the scene is projected.
Study NCT03956927 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Pre- and post-simulation administration of self-efficacy and anxiety questionnaires (IASTA Y1 and Y2)
Study NCT02690792 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NAFLD/NASH - Placebo
Description: Placebo capsules, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
Study NCT02690792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NAFLD/NASH - Vitamin E
Description: Vitamin E 200 IU capsule, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
Study NCT02378584 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: embryo transfer
Description: healthy blastocyst transfer in natural and hormonal cycle
Study NCT02378584 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: embryo transfer
Description: healthy blastocyst transfer in natural and hormonal cycle
Study NCT02498002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting with Weight Loss
Description: Alternate between 24 hour cycles of fasting and feeding with 150% of normal intake when feeding.
Study NCT02498002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting without Weight Loss
Description: Alternate between 24 hour cycles of fasting and feeding with 200% of normal intake when feeding.
Study NCT04081909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl，Remifentanil
Description: Patients in OBA ,anesthesia induction will receive fentanyl 2ug/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , remifentanil of 0.1- 0.2ug/ kg/ min.
Study NCT04081909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine,Dexmedetomidine
Description: Patients in OFA,anesthesia induction will receive ketamine 1 mg/kg ,propofol 1% 2-3mg/kg, rocuronium 0.6-1mg/kg. Anesthesia maintenance with 1.5-2% sevoflurane, propofol 1% 3-6mg/kg/hr , dexmedetomidine of 0.4-0.8ug/ kg/ hr.
Study NCT01549405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: İntercostal nerve block
Description: Nerve block group was administered two levels intercostal block (11 and 12th ribs) with 0.5% bupivacaine with epinephrine before surgery.
Study NCT01261897 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor-Canal-Blockade with Ropivacaine
Description: US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
Study NCT01261897 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Adductor-Canal-blockade with saline
Description: US-guided Adductor-Canal-blockade with saline
Study NCT04132687 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: autologous blood patch therapy
Description: use autologous blood as blood patch therapy in persistent air leak
Study NCT02321059 — intervention group
Intervention type: DEVICE
Intervention: Measurement of abdominal wall strength
Description: Test-retest examination of the reliability of the Goodstrength trunk dynamometer
Study NCT01954862 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air Insufflation method.
Description: Air Insufflation method.
Study NCT01954862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Description: CO2 insufflation.
Study NCT03249285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peri
Description: Perindopril 4 mg /day, orally with titration to 8 mg/day after 1 month if BP (Blood pressure) is not controlled
Study NCT03249285 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HCTZ
Description: Hydrochlorothiazide 12, 5 mg day, orally with titration to 25 mg/day after 1 month if BP is not controlled
Study NCT03249285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCTZ
Description: Hydrochlorothiazide 12, 5 mg day, orally with titration to 25 mg/day after 1 month if BP is not controlled
Study NCT03981133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: offer a pacifier
Description: offer a pacifier to normal newborn infants the first days of life
Study NCT03981133 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: no pacifier
Description: not to offer a pacifier at 15 days of life
Study NCT03740386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentolamine Mesylate 0.235 MG/ML [OraVerse]
Description: compare effect of phentolamine mesylate in three arms
Study NCT02721147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intimacy Enhancing Intervention
Description: Participants attend 4 intimacy enhancement intervention sessions over 75 minutes every other week for 4 weeks. The intimacy enhancement intervention comprises 4 main sessions: understanding impact of breast cancer on sex and intimacy, communication about sex/intimacy, problem-solving and changing thoughts, and planning ahead and preparing for challenges. Participants are encouraged to participate in written and behavioral activities at home.
Study NCT02721147 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living Healthy Together
Description: Participants receive educational information and support about breast cancer every other week for 4 weeks. The educational information and support comprises topics about breast cancer, its treatments, sleep, energy, stress, stress management, nutrition, and diet. Participants are encouraged to read educational materials.
Study NCT02721147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner-Assisted Coping Skills Training
Description: Receive couple-based intimacy enhancement intervention
Study NCT02721147 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral, Psychological or Informational Intervention
Description: Receive educational information and support
Study NCT03805022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 3 cycles.
Study NCT03805022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide or dacarbazine
Description: A treatment cycle consists of 3 weeks. Treatment may continue up to 3 cycles. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 3 cycles.
Study NCT03805022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: A treatment cycle consists of 3 weeks. Doxorubicin will be administered from day 1 to day 3 (60 or 75mg/m² day or 20 or 25 mg/m² per day), repeated every 3 weeks, up to 6 cycles.
Study NCT03805022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide or dacarbazine
Description: A treatment cycle consists of 3 weeks. Ifosfamide will be administered from day 1 to day 3 (7,5-9 g/m² over 3 days with mesna and G-CSF) or dacarbazine (100 mg/m² 1 day or 450 mg/m² 2 days) as per local practices, repeated every 3 weeks, up to 6 cycles.
Study NCT03805022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: At the discretion of the investigator
Description: Drug at the discretion of the investigator.
Study NCT02712944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Testosterone
Study NCT02712944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study NCT01289847 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gammaplex
Description: GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.
Study NCT01381133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chestnut Bloomington Outpatient (CBOP)
Description: CBOP is an evidence-informed intervention that has developed over 20 years and been shaped by treatment research. The underlying theory of change is that the combination of multiple evidence-based and best-practice treatment components will increase the adolescent's desire to change, provide the necessary skills, and create an environment supportive for this change. The intervention is based on a manual and is primarily delivered through skill and therapy groups, combined with a limited number of family and individual sessions for treatment planning and progress reviews.
Study NCT01381133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy/Cognitive Behavior Treatment (MET/CBT 7)
Description: A manual-based 5-session MET/CBT model was supplemented with 2 family sessions. First was a family session to provide parents with an overview. Next was an individual adolescent MET session that focused on building rapport, explaining treatment, building motivation, and reviewing personalized feedback. In the third session, the therapist helped the adolescent complete a functional analysis of substance use and a personal goal worksheet. During sessions 4-6, the adolescent joined a closed group of 6 for 90-min CBT skills groups focusing on substance refusal skills, enhancing social support, planning for high-risk situations, and coping with relapse. The last session was a family session to review progress, relapse signs, and continuing care plans. Treatment lasted about 12 weeks.
Study NCT01381133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assertive Continuing Care (ACC)
Description: ACC is a home-based continuing care approach that takes place over a 12-14 week period and has shown promise in a randomized clinical trial of adolescents discharged from residential treatment. Following an operant reinforcement and skills training model, ACC combines the Adolescent Community Reinforcement Approach and case management services to help adolescents and their caregivers engage in prosocial activities, skills, and needed community services during weekly home visits.
Study NCT04076774 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wondaleaf Female Condom
Description: Wondaleaf: Wondaleaf is an ultra thin (of 0.02 mm) polyurethane female/male condom (16x8cm) that has folded extended adhesive shields (front 18x18cm, back 18x10cm), which at unfolding covers the entire external genitalia to prevent direct skin contact and exchange of body fluid between sexual partners during intercourse. Insertion of the condom body into the vagina is through use of a small medical grade cotton tissue packed inside the foil package. This is inserted into the end of the condom body and used to push the condom into the vagina. Each condom is individually packaged without prior lubrication. However, lubricant is expected to be used at donning the condom and during sexual intercourse. The lubricant will be supplied in separate packets together with the condom. Unlike latex, polyurethane condoms are unlikely to cause any allergic reaction and are much stronger than conventional latex condoms
Study NCT04076774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wondaleaf Female Condom
Description: Wondaleaf: Wondaleaf is an ultra thin (of 0.02 mm) polyurethane female/male condom (16x8cm) that has folded extended adhesive shields (front 18x18cm, back 18x10cm), which at unfolding covers the entire external genitalia to prevent direct skin contact and exchange of body fluid between sexual partners during intercourse. Insertion of the condom body into the vagina is through use of a small medical grade cotton tissue packed inside the foil package. This is inserted into the end of the condom body and used to push the condom into the vagina. Each condom is individually packaged without prior lubrication. However, lubricant is expected to be used at donning the condom and during sexual intercourse. The lubricant will be supplied in separate packets together with the condom. Unlike latex, polyurethane condoms are unlikely to cause any allergic reaction and are much stronger than conventional latex condoms
Study NCT04076774 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FC2 Female Condom
Description: FC2: The FC2 is a second-generation female condom manufactured by the Female Health Company (Chicago, IL). The FC2 has US FDA approval and has been granted the CE Mark (Conformité Européenne) of the European Union. The FC2 is the only female condom that has been pre-qualified by the World Health Organisation. The device is similar in design to the FC1, but is made from a synthetic polymer (nitrile) film that is softer and more elastic than the polyurethane of the earlier device. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The outer ring at the open end is rolled from the nitrile material. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal polyurethane ring is removable and serves as the insertion mechanism and anchors the device within the vagina. FC2 measures 180mm in length and 80mm in lay-flat width. The device is pre-lubricated with dimethicone.
Study NCT04076774 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FC2 Female Condom
Description: FC2: The FC2 is a second-generation female condom manufactured by the Female Health Company (Chicago, IL). The FC2 has US FDA approval and has been granted the CE Mark (Conformité Européenne) of the European Union. The FC2 is the only female condom that has been pre-qualified by the World Health Organisation. The device is similar in design to the FC1, but is made from a synthetic polymer (nitrile) film that is softer and more elastic than the polyurethane of the earlier device. The condom is designed as a loose-fitting pouch that lines the vagina. It has two flexible rings. The outer ring at the open end is rolled from the nitrile material. The outer ring remains outside the vagina and covers the external genitalia during intercourse. An internal polyurethane ring is removable and serves as the insertion mechanism and anchors the device within the vagina. FC2 measures 180mm in length and 80mm in lay-flat width. The device is pre-lubricated with dimethicone.
Study NCT02051036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: In the moxibustion treatment group, 5 moxibustion points (bilateral SP6, LV3 and unilateral CV4) will be heated with indirect moxibustion (KangHwa, Korea).~The moxa pillars will be removed when the patient feel hotness and require to remove them.~The moxibustion will be conducted repeatedly unless patients feel the sense of heat up to seven times per session.
Study NCT00579111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: 10 mg/day IV daily for 3 days on days -6 to D-4. Campath may be omitted from the conditioning regimen for patients with malignant diseases and matched related donor transplants
Study NCT00579111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 3.2 mg/kg/day IV daily for 2 days, infused over 3 hours, on Day -5 and Day -4
Study NCT00579111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/day IV daily for 4 days on Day -5 to D -2
Study NCT00579111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic stem cell infusion
Description: Peripheral blood stem cells when possible. Bone marrow cells will be used if peripheral blood cells are insufficient or unavailable.
Study NCT00579111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK-506
Description: FK-506 at a dose of 0.03 mg/kd/day will be administered via continuous infusion over 24 hours from 4pm on Day -2 until engraftment or when the patient is able to take PO, then 0.03 mg/kg PO every 12 hours.
Study NCT03782428 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: 30 billions colony-forming unit (CFU) of a mixture of six viable strains including 107 mg of Lactobacillus acidophilus BCMC® 12130, Lactobacillus lactis BCMC® 12451, Lactobacillus casei subsp BCMC® 12313, Bifidobacterium longum BCMC® 02120, Bifidobacterium bifidum BCMC® 02290 and Bifidobacterium infantis BCMC® 02129
Study NCT03782428 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo samples produced were identical to the probiotics in term of taste and texture without live microorganisms.
Study NCT03943563 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dixon sequences acquisition
Description: Dixon sequences acquisition